InVivoMAb anti-human CD19
About InVivoMAb anti-human CD19
The 4G7 monoclonal antibody reacts with human CD19, a B cell-specific 95 kDa transmembrane glycoprotein of the immunoglobulin superfamily. CD19 contains two extracellular immunoglobulin-like domains and an extensive cytoplasmic tail. It functions as a positive regulator of B-cell receptor signaling in conjunction with CD21 and CD81. CD19 is highly expressed in most lymphomas and leukemias including some early B-cell malignancies that do not express CD20. For these reasons CD19 is quickly becoming an attractive alternative target for the immunotherapy of lymphoproliferative disorders.
InVivoMAb anti-human CD19 Specifications
|Recommended Isotype Control(s)||InVivoMAb mouse IgG1 isotype control, unknown specificity(BE0083)|
|Recommended InVivoPure Dilution Buffer||InVivoPure pH 7.0 Dilution Buffer(IP0070)|
Human chronic lymphocytic leukemia (CLL) cells
0.2 μM filtered
Purified from tissue culture supernatant in an animal free facility
The antibody solution should be stored undiluted at 4°C, and protected from prolonged exposure to light. Do not freeze.
References provided by Bioz:
Disclaimer: These articles are provided by Bioz, an automated third-party article search engine. Given Bioz’s automation, these articles may not reflect the reported applications listed for this product. For an extensive up-to-date article list directly tailored to the reported applications listed for this product please see the Bio X Cell Application References by clicking the green button above.
Powered by Bioz